Anne Robinson
Royal Alexandra Children's Hospital(GB)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Eosinophilic Esophagitis, Immunodeficiency and Autoimmune Disorders, Autoimmune and Inflammatory Disorders
Most-Cited Works
- → Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial(2017)892 cited
- → Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials(2022)369 cited
- → Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial(2022)299 cited
- → Adalimumab Induces Deep Remission in Patients With Crohn's Disease(2013)245 cited
- → Increased Risk of Malignancy With Adalimumab Combination Therapy, Compared With Monotherapy, for Crohn's Disease(2013)189 cited
- → Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease(2012)187 cited
- → Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3(2014)164 cited
- → Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis(2013)163 cited
- → Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study(2018)156 cited
- → One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2(2012)128 cited